Latest news
{{'2026-11-15T13:00:00Z' | dateFormatFilter}}
Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
{{'2026-11-14T17:15:00Z' | dateFormatFilter}}
Novo’s Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026
{{'2026-11-14T17:00:00Z' | dateFormatFilter}}
Novo’s investigational CagriSema, a GLP-1 and amylin analogue, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
